{"0": {
"doc":  "Ketamine",
"title": "Ketamine",
"content": "Mechanism of Action . NMDA Antagonist . Has little effect on [[Cerebral Blood Flow]] . Indications . Post-operative Analgesia 1 . | decreases pain scores | decreases opioid requirements | . Dosage . 0.15 mg/kg/hr . Complications . ![[Pasted image 20220106133946.png]] . Is technically a [[Seizure#Avoid pro-convulsants | Pro-convulsants]] . References . | Barash &amp;#8617; . | .",
"url": "/note/Ketamine"
},"1": {
"doc":  "Propofol",
"title": "Propofol",
"content": "See also [[Intravenous Anesthetics]] . Pharmacokinetics of Propofol . 2,6-diisopropylphenol . | formulation . | 1% aqueous solution | oil water emulsion containing . | soya bean oil, glycerol, egg licthin | . | . | Action . | Short initial distribution half life (2-8 min) | Elimination half life 4-7 hours due to . | distribution to fatty tissue | . | . | Metabolism . | Liver via conjugation to: . | glucuronide and sulphate which are excreted by . | kidneys | . | . | Extrahepatic metabolism | . | Context sensitive half life (infusion up to 8 hrs) . | 40 min | . | . Pharmacodynamics . | Cardiovascular . | SVR . | Reduces | . | Contractility . | reduces | . | Preload . | reduces | . | Heart Rate . | increases (baroreceptor mediated) | . | . | Respiratory . | profound respiratory depression | upper airway reflexes reduced | . | Cerebral . | CMR . | reduces | . | CBF . | reduces | . | Intracranial pressure . | down | . | Anticonvulsant properties . | at infusions | excititory in bolus | ~ | . | . | Hepatic . | Does not decrease hepatic blood flow (may increase) | . | . ## . Propofol Infusion Syndrome . References .",
"url": "/note/Propofol"
},"2": {
"doc":  "Post-operative Nausea and Vomiting",
"title": "Post-operative Nausea and Vomiting",
"content": "General Principles . | Anti-emetic medications are given routinely during anesthesia. | Combining agents of different classes reduces side effects and improves anti-emetic action | . Risk Factors for Nausea . Patient Risk Factors 1 . | Female | Non-smoker | history of PONV/motion sickness | post-operative opioids | . Surgical Risk Factors . | Cholecystectomy | laparoscopic | gynecologic Anesthetic Risk Factors . | Duration of anesthesia | use of volatile anesthetics / nitrous oxide | . Prevention of PONV . 5-HT\\(_3\\) Antagonists . [[Ondansetron]] . NK1 Receptor Antagonists . [[Aprepitant]] . Corticosteroids . [[Dexamethasone]] . Antidopaminergics . [[Haloperidol]] . | [[Tong J. Gan, Kumar G. Belani, Sergio Bergese, Frances Chung, Pierre Diemunsch, Ashraf S. Habib, Zhaosheng Jin, Anthony L. Kovac, Tricia A. Meyer, Richard D. Urman, Christian C. Apfel, Sabry Ayad, Linda Beagley, Keith Candiotti, Marina Englesakis, Traci L. Hedrick, Peter Kranke, Samuel Lee, Daniel Lipman, Harold S. Minkowitz, John Morton, Beverly K. Philip. 2020. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting . 411-448]] &amp;#8617; . | .",
"url": "/note/Post-operative-Nausea-and-Vomiting"
},"3": {
"doc":  "Airway Assessment",
"title": "Airway Assessment",
"content": "Airway Evaluation 1 . Overview . | Mouth opening | Mallampati score | Thyrdomental distance | Neck circumference | Neck range of motion | Status of dentition | NPO status Mallampati Score 2 . | . Predictors of Difficult Bag Mask Ventilation 3 . | Beard | Obesity (BMI &amp;gt;35) | Neck Circumference | Edentureless | Sleep Apnea | . Predictors of Difficult Direct Laryngoscopy 3 . | Mallampati 3&amp;amp;4 | Thyromental distance &amp;lt; 6cm | Limited C-spine extension | OSA | Increased neck range of motion | previous neck radiation | . | [[@butterworth2018morgan | J.F. Butterworth, D.C. Mackey, J.D. Wasnick, Morgan and mikhail&#39;s clinical anesthesiology, 6th edition, 2018]] | . &amp;#8617; . | | [[@pardo2017basics | M. Pardo, R.D. Miller, Basics of anesthesia E-book, 2017]] | . &amp;#8617; . | | [[@lawCanadianAirwayFocus2021a | J. Adam Law, Laura V. Duggan, Mathieu Asselin, Paul Baker, Edward Crosby, Andrew Downey, Orlando R. Hung, George Kovacs, François Lemay, Rudiger Noppens, Matteo Parotto, Roanne Preston, Nick Sowers, Kathryn Sparrow, Timothy P. Turkstra, David T. Wong, Philip M. Jones, undefined undefined, Canadian Airway Focus Group updated consensus-based recommendations for management of the difficult airway: part 2. Planning and implementing safe management of the patient with an anticipated difficult airway, 2021]] | . &amp;#8617; &amp;#8617;2 . | .",
"url": "/note/Airway-Assessment-Pocket-Card"
},"4": {
"doc":  "Clerkship Resources",
"title": "Clerkship Resources",
"content": "The following topics are taken from the Anesthesia Clerkship Core Documents. The following collection can serve as memory aids for some key topics, but does not include an exhaustive overview. Intra-operative Monitoring . Fluid Management . Physiology . Pharmacology . Airway Mechanical Skills . Ventilation Management . Pain Management . [[Pain Management]] . Pre-operative Evaluation . [[Airway Assessment Pocket Card]] . Post-operative Management .",
"url": "/note/Clerkship-Resources"
},"5": {
"doc":  "NSAID",
"title": "NSAID",
"content": "Mechanism of Action . Inhibit COX enzyme which prevents prostaglandins from being formed (which are inflammatory mediators) 1 . COX 1 . maintain normal renal function, GI tract mucosal protection, thromboxane . COX 2 . Mediates pain, fever, inflammation . Examples . [[Ibuprofen]] [[Ketorolac]] . NSAID Complications . Generally, the complications are a result of inhibiting COX-1 . | Dyspepsia, GIT ulceration | Platelet dysfunction | Renal impairment by inhibiting PG induced vasodilation of afferent glomerular arterioles | . Inhibition of COX-2 has been linked to several adverse cardiac outcomes. References . | [[@shaferStoeltingPharmacologyPhysiology2015 | Steven L. Shafer, James P. Rathmell, Pamela Flood, Stoelting&#39;s pharmacology and physiology in anesthetic practice, 2015]] | . &amp;#8617; . | .",
"url": "/note/NSAID"
},"6": {
"doc":  "Pain Management",
"title": "Pain Management",
"content": "Definitions . | Multimodal Analgesia - use of different classes of drugs to optimize analgesia while minimizing individual drug side-effects | . WHO Pain Ladder . Step 1 - Non-opioids +/- Adjuvants . [[Acetaminophen]] . [[NSAID]] . | [[Ibuprofen]] | [[Ketorolac]] Step 2 - Opioids for Mild-moderate Pain . | . Step 3 - Opioids for Moderate-Severe Pain .",
"url": "/note/Pain-Management"
},"7": {
"doc":  "Acetaminophen",
"title": "Acetaminophen",
"content": "Mechanism of Action . Possibly involves direct and indirect inhibition of central cyclooxygenases + activation of the endocannabinoid system + spinal serotonergic pathways . Indications . [[Pain Management#Step 1 - Non-opioids +/- Adjuvants]] . Dosage . Healthy Patient . 625 - 1000 mg PO Q4hrs to a daily max dose of 4000 mg . Complications . Liver toxicity can occur in overdose or in patients with impaired hepatic function . References .",
"url": "/note/Acetaminophen"
},"8": {
"doc":  "Ibuprofen",
"title": "Ibuprofen",
"content": "Mechanism of Action . Indications . Dosage . 400 - 600 mg PO TID - QID . ![[NSAID#Complications]] . References .",
"url": "/note/Ibuprofen"
},"9": {
"doc":  "Hydromorphone",
"title": "Hydromorphone",
"content": "Mechanism of Action . Dosage . Epidural Dosing . Bupivicaine and hydromorphone . | hydromorphone 8mcg/mL, bupivicaine 0.1%. | hydromorphone doses can range from 4mcg/mL to 20mcg/mL bupivicaine (0.1 mg/mL) Complications . | . References .",
"url": "/note/Hydromorphone"
},"10": {
"doc":  "Ketorolac",
"title": "Ketorolac",
"content": "Mechanism of Action . Non-selective COX inhibitor see [[NSAID]] 1 . Pharmacology . Half-life 2.5-8.5 hrs 1 Metabolised by conjugation . Indications . [[Pain Management#Step 1 - Non-opioids +/- Adjuvants]] . Dosage . 15-30 mg IV/IM q6-24 hrs . Complications . ![[NSAID#NSAID Complications]] . References . | [[@shaferStoeltingPharmacologyPhysiology2015 | Steven L. Shafer, James P. Rathmell, Pamela Flood, Stoelting&#39;s pharmacology and physiology in anesthetic practice, 2015]] | . &amp;#8617; &amp;#8617;2 . | .",
"url": "/note/Ketorolac"
},"11": {
"doc":  "Ondansetron",
"title": "Ondansetron",
"content": "Mechanism of Action . 5-HT3 antagonist . Indications . [[Post-operative Nausea and Vomiting]] NNT 6 for postoperative nausea and 7 for postoperative vomiting . Dosage . 4 mg IV or 8mg PO disolving (50% bioavailable) 1 . Complications . NNH 36 for headache NNH 31 for elevated LFTs NNH 23 for constipation . References . | [[@ganFourthConsensusGuidelines2020 | Tong J. Gan, Kumar G. Belani, Sergio Bergese, Frances Chung, Pierre Diemunsch, Ashraf S. Habib, Zhaosheng Jin, Anthony L. Kovac, Tricia A. Meyer, Richard D. Urman, Christian C. Apfel, Sabry Ayad, Linda Beagley, Keith Candiotti, Marina Englesakis, Traci L. Hedrick, Peter Kranke, Samuel Lee, Daniel Lipman, Harold S. Minkowitz, John Morton, Beverly K. Philip, Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, 2020]] | . &amp;#8617; . | .",
"url": "/note/Ondansetron"
},"12": {
"doc":  "Airway Devices",
"title": "Airway Devices",
"content": "Oropharyngeal Airway . Useful for maintaining airway patency Sizing: corner of mouth to angle of mandible Contraindications: beware in pediatrics (due to incompletely formed hard palate) . Nasopharyngeal Airway . Also known as a nasal trumpet Used to maintain airway patency Sizing: tip of nose to earlobe Contraindications: Basal skull fracture, patients likely to have epistaxis (relative) . Laryngeal Mask Airway . A supraglottic (does not pass below vocal cords) airway device which can be used to maintain an airway under anesthesia or in an emergency situation. These devices do not provide the level of seal that an ETT does . Indications . | anesthetic cases with: . | good access to the airway (to swap to ETT, if needed) | positioning amenable to low airway pressures | generally, no laparopscopic component | . | Patients at risk of laryngospasm/bronchospasm . | less invasive and provoking than an ETT Contraindications . Patient Factors . | . | Severe GERD | Obesity . | due to higher pressures required Surgical . | . | laparoscopic (generally) | shared airway with limited access to manage airway Sizing . These are weight based and vary by type LMA . Endotracheal Tube . Placement . Standard endotracheal tubes are placed below the level of the vocal cords under direct vision. On x-ray, the tube tip should sit 2-4 cm above the carina. A rule of thumb for the depth of tube is: \\(Depth = 3\\times Tube~Diameter\\) . Sizing . Tube diameter is generally selected with the following rule for cuffed tubes: \\(Tube~Diameter = (age + 4)/4\\) . | . Specialized Endotracheal Tubes . RAE tubes . Stands for: Ring, Adair, Elwyn Charicteristic bend removes tube and circuit from surgical field Useful in: Sinus surgery, facial surgery Special considerations: Fixed length from bend to tip of tube can impair proper tube placement below glottis . Nasal RAE . Special Considerations: . | Fixed length from bend to tip of tube can impair proper tube placement below glottis | . Cuffed vs Uncuffed . Generally cuffed tubes are used unless in very small pediatric populations .",
"url": "/note/Airway-Devices"
},"13": {
"doc":  "Aprepitant",
"title": "Aprepitant",
"content": "Mechanism of Action . Pharmacology . Half life is 40 hours . Indications . [[Post-operative Nausea and Vomiting]] . | reduces incidence of POV (not nausea) | More efficacious than [[Ondansetron]]1 | Useful as a prophylactic anti-emetic Dosage . 40, 80, 125 mg PO are all effective . Complications . | . References . | [[Tong J. Gan, Kumar G. Belani, Sergio Bergese, Frances Chung, Pierre Diemunsch, Ashraf S. Habib, Zhaosheng Jin, Anthony L. Kovac, Tricia A. Meyer, Richard D. Urman, Christian C. Apfel, Sabry Ayad, Linda Beagley, Keith Candiotti, Marina Englesakis, Traci L. Hedrick, Peter Kranke, Samuel Lee, Daniel Lipman, Harold S. Minkowitz, John Morton, Beverly K. Philip, Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, 2020]] &amp;#8617; . | .",
"url": "/note/Aprepitant"
},"14": {
"doc":  "Dexamethasone",
"title": "Dexamethasone",
"content": "Mechanism of Action . Indications . [[Post-operative Nausea and Vomiting]] . | dosed at beginning of case Dosage . [[Post-operative Nausea and Vomiting]] . | ranges from 4-10 mg IV | No difference in anti-emetic action of 4 vs 8 Complications . Does not appear to increase post-op infection rates 12 . | . Does not significantly increase risk of bleeding Does not appear to increase cancer risk 2 . References . | [[@corcoranDexamethasoneSurgicalSiteInfection2021 | Tomás B. Corcoran, Paul S. Myles, Andrew B. Forbes, Allen C. Cheng, Leon A. Bach, Edmond O’Loughlin, Kate Leslie, Matthew T.V. Chan, David Story, Timothy G. Short, Catherine Martin, Pauline Coutts, Kwok M. Ho. 2021. Dexamethasone and Surgical-Site Infection . 1731-1741]] | . &amp;#8617; . | | [[@ganFourthConsensusGuidelines2020 | Tong J. Gan, Kumar G. Belani, Sergio Bergese, Frances Chung, Pierre Diemunsch, Ashraf S. Habib, Zhaosheng Jin, Anthony L. Kovac, Tricia A. Meyer, Richard D. Urman, Christian C. Apfel, Sabry Ayad, Linda Beagley, Keith Candiotti, Marina Englesakis, Traci L. Hedrick, Peter Kranke, Samuel Lee, Daniel Lipman, Harold S. Minkowitz, John Morton, Beverly K. Philip, Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting, 2020]] | . &amp;#8617; &amp;#8617;2 . | .",
"url": "/note/Dexamethasone"
},"15": {
"doc":  "Haloperidol",
"title": "Haloperidol",
"content": "Mechanism of Action . Indications . [[Post-operative Nausea and Vomiting]] . Dosage . [[Post-operative Nausea and Vomiting]] . | 0.5 - 1 mg IV at the beginning or end of surgery Complications . | QTC prolongation | . References .",
"url": "/note/Haloperidol"
}
}